Actinogen Medical Limited ACW

Actinogen Medical CFO Will Souter talked with Proactive about the completion of the final patient visit in the company’s pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial and what investors can expect ahead of top-line results in November. Souter described the final patient visit as “a major milestone in any clinical trial”, noting that XanaMIA has progressed through an interim analysis and three meetings of its independent data monitoring committee. He also highlighted the significant time and effort involved in running the study, with patients undergoing treatment for 36 months. Looking a

This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36-week treatment periodSYDNEY, Australia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that, following the final participant visit on 22 September in the USA, topline results for the XanaMIA phase 2b/3 Alzheimer’s disease (AD) clinical tria

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial, keeping topline results from the closely watched study on track for release in November. The final participant visit took place in the United States,...

Actinogen Medical CEO Dr Steven Gourlay talked with Proactive about the company’s approach to targeting elevated brain cortisol with its investigational drug Xanamem, and the upcoming clinical trial readout assessing its potential to slow functional and cognitive decline in Alzheimer’s disease. The company's current study involves 247 patients and is designed to assess whether Xanamem can significantly slow functional and cognitive decline compared with placebo. Results are expected in November. He also outlined the potential next steps if results are positive, including discussions with regul

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has secured approximately $4.77 million in additional funding after Forrest Capital Pty Ltd agreed to fully underwrite the exercise of the company’s remaining unlisted options. The agreement comes as Actinogen approaches a potentially significant...

Actinogen Medical CFO Will Souter talked with Proactive about the company’s FY2026 milestones, its upcoming XanaMIA Alzheimer’s disease trial results in November, and the priorities that could shape its progress through FY2027. Souter said the past year had been significant for Actinogen Medical, with the current Alzheimer’s disease study nearing completion after several years of work. “It’s been a big journey and the guys have done an amazing job to bring it all the way to the conclusion that’s just around the corner with results in November. Alongside progress with XanaMIA, Souter highlighte

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is approaching a potentially defining catalyst for its lead Alzheimer’s disease therapy Xanamem, with topline results from the pivotal XanaMIA Phase 2b/3 trial expected in November 2026. The company noted in its FY26 results that the study remained...

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) will host a Clinical Trials Science Forum webinar today examining the future of Alzheimer’s disease treatment, as the company advances its lead drug candidate Xanamem® toward a pivotal clinical trial readout expected in November 2026. The live...

The S&P/ASX Small Ordinaries Index (ASX) closed yesterday at 3,570.80 points, up 0.60% or 21.30 points for the session. The index has gained 4.33%, or 148.30 points, over the past five trading days, reflecting a strong recent run for the small-cap end of the Australian market. Against...

The S&P/ASX Small Ordinaries Index (ASX) closed at 3,482.30 on Wednesday, August 5, gaining 80.50 points or 2.37%. The index has risen 170.20 points, or 5.14%, over the past 5 trading days. While it's still quiet for small cap newsflow, companies across the healthcare, critical...

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® (emestedastat) as a potential treatment for Alzheimer’s disease, with results from the company’s first pivotal clinical trial expected in November 2026. The company...

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is approaching a defining clinical milestone as it advances Xanamem, a once-daily oral therapy designed to slow Alzheimer’s disease by controlling elevated cortisol in the brain. The company’s fully enrolled XanaMIA Phase 2b/3 trial is expected to...

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week reported continued progress across its clinical, regulatory and financial programs during the June quarter, with the pivotal XanaMIA Alzheimer’s disease trial remaining on schedule to deliver topline results in November...

Actinogen Medical Ltd managing director and CEO Dr Steven Gourlay talked with Proactive about the company’s June quarter progress, including preparations for the pivotal XanaMIA Alzheimer’s disease trial topline results expected in November 2026. Gourlay said the fully enrolled Phase 2b/3 trial remained on schedule, with treatment, follow-up and data-cleaning activities continuing across participating sites. He described the upcoming readout as “a potentially transformational event for the company and for the clinical science, and for patients with Alzheimer’s all around the world.” An indepen

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has maintained momentum across its clinical, regulatory and commercial programs during the June quarter, with its pivotal XanaMIA Alzheimer’s disease trial on schedule to deliver topline results in November 2026. The fully enrolled Phase 2b/3 trial...

Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this yearSYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that results from its proof-of-concept trial, entitled “A phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder (MDD) and cognitive impairment (CI)” have been published as a peer-reviewed article in the British Journal of P

XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces the successful outcome of its scheduled scientific advice meeting (written response) on Alzheimer’s disease (AD) with the European Medicines Agency (EMA). Actinogen and the EMA reached a common understanding of the pathway to marketing approval for AD in the European Unio

Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial following completion of 36 weeks of treatment in the randomized phase. Highlights of the OLE: Open-label phase of up to 25 months duration, during which all participants will receive